Trial Profile
A Phase 1/2, Open-Label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamic Activity, and Efficacy of SNDX- 6352 in Subjects With Chronic Graft Versus Host Disease Who Have Received at Least 2 Lines of Prior Therapy
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 03 Jan 2024
Price :
$35
*
At a glance
- Drugs Axatilimab (Primary)
- Indications Graft-versus-host disease
- Focus Adverse reactions; Therapeutic Use
- Sponsors Syndax Pharmaceuticals
- 02 Jan 2024 According to a Syndax Pharmaceuticals media release, Results published in the Journal of Clinical Oncology
- 30 May 2023 Planned End Date changed from 15 Feb 2023 to 1 Dec 2023.
- 24 May 2023 Results presented at the 119th International Conference of the American Thoracic Society